Moderna’s Q1 2026 results spotlight a strategic pivot from COVID-centered revenues toward broader infectious disease, oncology, and rare disease assets. The company’s proprietary mRNA platform underpins a growing pipeline including combination flu-COVID vaccines, personalized cancer therapies in partnership with Merck, and rare metabolic disorder treatments. However, seasonal vaccine demand variability and evolving regulatory landscapes temper near-term commercial visibility. Operational scale and AI integration support cost efficiency efforts as Moderna seeks sustained growth beyond its initial pandemic blockbuster products.